
Eric L. Bolda
Examiner (ID: 16664, Phone: (571)272-8104 , Office: P/3645 )
| Most Active Art Unit | 3645 |
| Art Unit(s) | 3663, 3645 |
| Total Applications | 1609 |
| Issued Applications | 1332 |
| Pending Applications | 112 |
| Abandoned Applications | 196 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19479789
[patent_doc_number] => 20240327831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 18/257547
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257547
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/257547 | COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY | Dec 21, 2021 | Pending |
Array
(
[id] => 18020974
[patent_doc_number] => 20220372473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => ANTISENSE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/553602
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553602
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553602 | ANTISENSE COMPOUNDS AND USES THEREOF | Dec 15, 2021 | Abandoned |
Array
(
[id] => 17704966
[patent_doc_number] => 20220204972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => Antisense oligonucleotides for the treatment of Stargardt disease
[patent_app_type] => utility
[patent_app_number] => 17/552372
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32331
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552372
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/552372 | Antisense oligonucleotides for the treatment of Stargardt disease | Dec 15, 2021 | Issued |
Array
(
[id] => 18938238
[patent_doc_number] => 20240033377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => AAV VECTORS FOR GENE EDITING
[patent_app_type] => utility
[patent_app_number] => 18/266076
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 112059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -173
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266076
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/266076 | AAV VECTORS FOR GENE EDITING | Dec 8, 2021 | Pending |
Array
(
[id] => 17482575
[patent_doc_number] => 20220090079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/544801
[patent_app_country] => US
[patent_app_date] => 2021-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17544801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/544801 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | Dec 6, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 18879465
[patent_doc_number] => 20240002834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => ADENINE BASE EDITOR LACKING CYTOSINE EDITING ACTIVITY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/039632
[patent_app_country] => US
[patent_app_date] => 2021-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039632
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039632 | ADENINE BASE EDITOR LACKING CYTOSINE EDITING ACTIVITY AND USE THEREOF | Nov 30, 2021 | Pending |
Array
(
[id] => 17458725
[patent_doc_number] => 20220072029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => BI SPECIFIC APTAMER
[patent_app_type] => utility
[patent_app_number] => 17/537195
[patent_app_country] => US
[patent_app_date] => 2021-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537195
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/537195 | Bi specific aptamer | Nov 28, 2021 | Issued |
Array
(
[id] => 17996727
[patent_doc_number] => 11497814
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Compositions and methods of treating muscle atrophy and myotonic dystrophy
[patent_app_type] => utility
[patent_app_number] => 17/529197
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 69
[patent_figures_cnt] => 99
[patent_no_of_words] => 62670
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529197 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Nov 16, 2021 | Issued |
Array
(
[id] => 18186421
[patent_doc_number] => 11576980
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-14
[patent_title] => Compositions and methods of treating muscle atrophy and myotonic dystrophy
[patent_app_type] => utility
[patent_app_number] => 17/529207
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 74
[patent_figures_cnt] => 99
[patent_no_of_words] => 65348
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529207
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529207 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Nov 16, 2021 | Issued |
Array
(
[id] => 17460613
[patent_doc_number] => 20220073918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
[patent_app_type] => utility
[patent_app_number] => 17/528383
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21899
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528383
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/528383 | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat | Nov 16, 2021 | Issued |
Array
(
[id] => 17579119
[patent_doc_number] => 20220135974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
[patent_app_type] => utility
[patent_app_number] => 17/524323
[patent_app_country] => US
[patent_app_date] => 2021-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42418
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17524323
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/524323 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | Nov 10, 2021 | Pending |
Array
(
[id] => 17563466
[patent_doc_number] => 20220127615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/523030
[patent_app_country] => US
[patent_app_date] => 2021-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82331
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523030
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/523030 | Coronavirus IRNA compositions and methods of use thereof | Nov 9, 2021 | Issued |
Array
(
[id] => 17595303
[patent_doc_number] => 20220144876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => Deuterium-Stabilised Ribonucleic Acid (RNA) Molecules Displaying Increased Resistance to Thermal and Enzymatic Hydrolysis, Aqueous Compositions Comprising Stabilised RNA Molecules and Methods for Making Same
[patent_app_type] => utility
[patent_app_number] => 17/522946
[patent_app_country] => US
[patent_app_date] => 2021-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11816
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522946
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522946 | Deuterium-stabilised ribonucleic acid (RNA) molecules displaying increased resistance to thermal and enzymatic hydrolysis, aqueous compositions comprising stabilised RNA molecules and methods for making same | Nov 9, 2021 | Issued |
Array
(
[id] => 19411996
[patent_doc_number] => 12077803
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => MicroRNAs as biomarkers for endometriosis
[patent_app_type] => utility
[patent_app_number] => 17/517014
[patent_app_country] => US
[patent_app_date] => 2021-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 25973
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517014
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/517014 | MicroRNAs as biomarkers for endometriosis | Nov 1, 2021 | Issued |
Array
(
[id] => 18903037
[patent_doc_number] => 20240018522
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING
[patent_app_type] => utility
[patent_app_number] => 18/033748
[patent_app_country] => US
[patent_app_date] => 2021-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24900
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033748
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/033748 | OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING | Oct 25, 2021 | Pending |
Array
(
[id] => 17595725
[patent_doc_number] => 20220145299
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => CTLA-4 APTAMER CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/452172
[patent_app_country] => US
[patent_app_date] => 2021-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17452172
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/452172 | CTLA-4 aptamer conjugates | Oct 24, 2021 | Issued |